Can angiotensin-converting enzyme inhibitors reverse atherosclerosis?

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Angiotensin II is a potent vasoconstrictor found in the vascular endothelium.
• Angiotensin-converting enzyme (ACE) inhibitors block angiotensin II formation, lowering blood pressure and aiding heart failure.
• ACE inhibitors offer benefits beyond hemodynamics, impacting vascular function and cardiovascular events.

Purpose of the Study:

• To explore the multifaceted benefits of ACE inhibitors.
• To investigate the mechanisms behind ACE inhibitors' effects on vascular function and cardiovascular events.
• To assess the impact of ACE inhibitors on atherosclerosis and plaque stability.

Main Methods:

• Review of existing studies on ACE inhibitors and cardiovascular outcomes.
• Analysis of the effects of ACE inhibitors on local endocrine pathways and inflammatory processes.
• Evaluation of evidence regarding ACE inhibitors' influence on atherosclerotic plaque progression and stability.

Main Results:

• ACE inhibitors demonstrate beneficial hemodynamic effects, improving blood pressure and heart failure.
• These agents positively influence vascular function and prevent cardiovascular events.
• Evidence suggests ACE inhibitors may slow atherosclerotic lesion progression and stabilize plaques.
• Modulation of inflammatory pathways by ACE inhibitors may reduce the risk of plaque rupture.

Conclusions:

• ACE inhibitors provide significant cardiovascular benefits beyond blood pressure reduction.
• Their impact on vascular inflammation and atherosclerosis contributes to preventing adverse cardiovascular events.
• ACE inhibitors may play a crucial role in managing patients at risk for coronary artery disease by stabilizing plaques.